(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[(1-amino-4-phenyl-cyclohexanecarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-oxo-butanoyl]amino]-4-methyl-pentanoyl]amino]hexanoyl]amino]-6-guanidino-hexanoyl]amino]-3-methyl-pentanoyl]amino]acetyl]amino]-4-methyl-pentanoyl]amino]-4-methyl-pentanoyl]amino]-5-guanidino-pentanoic acid

ID: ALA5278470

Chembl Id: CHEMBL5278470

Max Phase: Preclinical

Molecular Formula: C73H118N20O13

Molecular Weight: 1483.87

Associated Items:

Names and Identifiers

Canonical SMILES:  CC[C@H](C)[C@H](NC(=O)[C@H](CCCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)C1(N)CCC(c2ccccc2)CC1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O

Standard InChI:  InChI=1S/C73H118N20O13/c1-9-44(8)60(68(103)84-40-59(95)85-53(34-41(2)3)63(98)89-55(36-43(6)7)65(100)88-52(69(104)105)26-19-33-82-72(78)79)93-62(97)51(25-16-18-32-81-71(76)77)86-61(96)50(24-15-17-31-74)87-64(99)54(35-42(4)5)90-67(102)57(38-58(75)94)91-66(101)56(37-47-39-83-49-23-14-13-22-48(47)49)92-70(106)73(80)29-27-46(28-30-73)45-20-11-10-12-21-45/h10-14,20-23,39,41-44,46,50-57,60,83H,9,15-19,24-38,40,74,80H2,1-8H3,(H2,75,94)(H,84,103)(H,85,95)(H,86,96)(H,87,99)(H,88,100)(H,89,98)(H,90,102)(H,91,101)(H,92,106)(H,93,97)(H,104,105)(H4,76,77,81)(H4,78,79,82)/t44-,46?,50-,51-,52-,53-,54-,55-,56-,57-,60-,73?/m0/s1

Standard InChI Key:  GNPNHJBMXRSFCP-LQPPUZIUSA-N

Alternative Forms

  1. Parent:

    ALA5278470

    ---

Associated Targets(Human)

PCSK9 Tclin Subtilisin/kexin type 9 (362 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 1483.87Molecular Weight (Monoisotopic): 1482.9187AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Ahamad S, Bhat SA..  (2022)  Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment.,  65  (23.0): [PMID:36446632] [10.1021/acs.jmedchem.2c01290]

Source